Trending at Lumira Ventures

Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)

Alyssia Watkin Portfolio News, Medexus Pharmaceuticals

Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s fourth fiscal quarter and fiscal year ended March 31, 2022. All dollar amounts in this press release are in United States …

Corvia Medical Closed $54 Million Financing to Support Planned Confirmatory Trial of the Corvia® Atrial Shunt

Alyssia Watkin Portfolio News, Corvia Medical, Main Page

Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients TEWKSBURY, Mass., June 9, 2022 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced the closing of a $54 million equity financing …

XyloCor Therapeutics Presents Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina

Alyssia Watkin Portfolio News, Xylocor Therapeutics, Main Page

Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study Preliminary efficacy data highlight XC001 …